Jan 31, 2025 · Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14. learn about our pipeline Axsome focuses on CNS conditions including depression, …

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of …

leave axsome.com. You will now be sent to a website that is not controlled or owned by Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for the website you …

Get information on Axsome products that are currently in-market, developed to find new ways to solve treatment gaps in CNS conditions.

AXS-05 (dextromethorphan-bupropion) is a novel, oral, NMDA receptor antagonist being developed for the treatment of multiple CNS conditions. Learn more and see clinical and …

View a list of current career opportunities at Axsome Therapeutics and submit an application.

What is Major Depressive Disorder? Major Depressive Disorder (MDD) is a serious, biologically-based disorder: It is prevalent and debilitating, and can be chronic and life-threatening—in …

Axsome Therapeutics is a biopharmaceutical company committed to developing therapies that transform patients’ lives. We’re creative, entrepreneurial, and growing! Interested in joining us? …

Agitation is reported in about 70% of people living with Alzheimer's disease (AD). Learn about Axsome's work in agitation in patients with AD, key facts and the unmet needs.

Migraine is common and debilitating, affecting over 37 million Americans. Learn about Axsome's work in migraine, key facts and the unmet needs of patients.